Seribantumab Explained

Seribantumab (INN;[1] development code MM-121) is a monoclonal antibody designed for the treatment of cancer.[2] It binds to extracellular domain of HER3 blocking NRG1 binding and thereby preventing the activation of the receptor.[3]

This drug was developed by Sanofi/Merrimack Pharmaceuticals, Inc.

Notes and References

  1. . International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 108 . WHO Drug Information . 26 . 4 . 2012 .
  2. http://www.ama-assn.org/resources/doc/usan/x-pub/seribantumab.pdf Statement On A Nonproprietary Name Adopted By The USAN Council - Seribantumab
  3. Rendell A, Thomas-Bland I, McCuish L, Taylor C, Binju M, Yu Y . Targeting Tyrosine Kinases in Ovarian Cancer: Small Molecule Inhibitor and Monoclonal Antibody, Where Are We Now? . Biomedicines . 10 . 9 . August 2022 . 2113 . 36140214 . 9495728 . 10.3390/biomedicines10092113 . free .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Seribantumab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.